Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
Type 2 Diabetes
TYPE 2 DIABETES
-
-
In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D
Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes. -
Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?
Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD on the risk of developing T2D. -
Addressing Psychological Insulin Resistance in Patients With Diabetes
Learn about strategies to reduce a patient’s reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.
Video
Latest News
New Medicare Benefit Would Limit Insulin Copays to $35 a Month
Reacting to skyrocketing prices for insulin, the Trump Administration announced on Tuesday a new benefit that would limit Medicare recipients’ copays for insulin to a maximum of $35 a month and save them about $446 a year if they have prescription plans that offer the benefit.
Implementing CGM for Hospitalized Patients With COVID-19 and Diabetes: Insights From One Medical Center
In-hospital use of continuous glucose monitoring may offer improvements in glycemic control and reduced exposure to COVID-19 for healthcare professionals.
Considerations for Hydroxychloroquine Use in Patients With Diabetes
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
Liver Forum Releases Guidelines for Assessing Patients With NASH
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
Reduction in Left Ventricular Mass With Empagliflozin Not Mediated Through Effect on Diastolic Function
The reduction in left ventricular mass observed in patients with stable coronary artery disease and type 2 diabetes treated with empagliflozin may not result of an effect of this drug on diastolic function.
No Causal Link Found Between Obesity and Thyroid Cancer Risk
In Mendelian randomization analyses, obesity was not causatively linked to either benign nodular thyroid disease or thyroid cancer.
Updated Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Larger Genetically Predicted Body Size in Childhood Linked to CAD, T2D in Adulthood
Large adult body size contributes to the association between genetically predicted larger body size in childhood and coronary artery disease and type 2 diabetes later in life.
Greater Reductions in HbA1c, Weight Observed With Higher Dulaglutide Dose
Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D) compared with dulaglutide 1.5mg.
Diabetes Linked to Worse Cognitive Impairment After Stroke, but No Association Found for Prediabetes
Prediabetes is not associated with cognition after stroke, whereas type 2 diabetes increases the risk for lower poststroke cognitive function.
Want to read more?
Please login or register first to view this content.
Next post in Type 2 Diabetes
